Skip to main content
. Author manuscript; available in PMC: 2016 Jan 9.
Published in final edited form as: Vaccine. 2014 Nov 30;33(3):430–436. doi: 10.1016/j.vaccine.2014.11.042

Table 1.

Group Immunogen Survival Antibody titer (EC50)
Neutralization titer (ED50)
Detectable LF IgG/IgM Inhaled spore dose
Pre-challenge Post-challenge Pre-challenge Post-challenge Post-challenge (LD50 ± SD)
1 BT-LND(2) 7/7a 38,427 32,949 1813 4876 1/7 204 ± 43
2 TB-LND(2) 7/7a 57,185 51,381 4764 8,751b 0/7 195 ± 46
3c PA 7/7a 82,651 76,336 1954 836d 0/7 196 ± 44
4c Control MAP 0/9 ND ND ND ND ND 186 ± 52
5c Naïve 0/6 ND ND ND ND ND 202 ± 45

Pre- and post-challenge titers shown are geometric mean titers.

a

p < 0.0001, compared to Naïve, Mantel–Cox log-rank test.

b

p = 0.031, Wilcoxon matched-pairs signed rank test.

c

Control groups reported previously.

d

p = 0.016, Wilcoxon matched-pairs signed rank test.